CN113679751A - Application of extract in preparation of medicines for reducing morphine-induced hepatotoxicity - Google Patents
Application of extract in preparation of medicines for reducing morphine-induced hepatotoxicity Download PDFInfo
- Publication number
- CN113679751A CN113679751A CN202110991802.3A CN202110991802A CN113679751A CN 113679751 A CN113679751 A CN 113679751A CN 202110991802 A CN202110991802 A CN 202110991802A CN 113679751 A CN113679751 A CN 113679751A
- Authority
- CN
- China
- Prior art keywords
- morphine
- extract
- group
- days
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 title claims abstract description 178
- 229960005181 morphine Drugs 0.000 title claims abstract description 89
- 231100000304 hepatotoxicity Toxicity 0.000 title claims abstract description 26
- 239000003814 drug Substances 0.000 title claims abstract description 24
- 206010019851 Hepatotoxicity Diseases 0.000 title claims abstract description 22
- 230000007686 hepatotoxicity Effects 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims description 12
- 229940079593 drug Drugs 0.000 title description 4
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 54
- 241000699670 Mus sp. Species 0.000 claims description 27
- 241000628997 Flos Species 0.000 claims description 20
- 230000000694 effects Effects 0.000 claims description 13
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 9
- 230000003203 everyday effect Effects 0.000 claims description 9
- 210000005228 liver tissue Anatomy 0.000 claims description 9
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 8
- 238000002474 experimental method Methods 0.000 claims description 8
- 230000007935 neutral effect Effects 0.000 claims description 8
- 210000002966 serum Anatomy 0.000 claims description 7
- 206010039897 Sedation Diseases 0.000 claims description 6
- 210000000683 abdominal cavity Anatomy 0.000 claims description 6
- 230000036280 sedation Effects 0.000 claims description 6
- 208000037816 tissue injury Diseases 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 230000007056 liver toxicity Effects 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 230000001681 protective effect Effects 0.000 claims description 4
- 239000011347 resin Substances 0.000 claims description 4
- 229920005989 resin Polymers 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000002504 physiological saline solution Substances 0.000 claims description 3
- 239000012192 staining solution Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 206010067125 Liver injury Diseases 0.000 abstract description 6
- 230000001624 sedative effect Effects 0.000 abstract description 6
- 231100000753 hepatic injury Toxicity 0.000 abstract description 5
- 241000196324 Embryophyta Species 0.000 abstract description 3
- 239000002671 adjuvant Substances 0.000 abstract description 3
- 241000411851 herbal medicine Species 0.000 abstract description 3
- 210000001519 tissue Anatomy 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 210000002989 hepatic vein Anatomy 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 231100000334 hepatotoxic Toxicity 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229940124636 opioid drug Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses application of an extract in preparing a medicament for reducing morphine-induced hepatotoxicity, wherein the extract is a honeysuckle extract, and the invention develops new clinical application of the traditional Chinese herbal medicine honeysuckle extract. The honeysuckle extract can obviously inhibit morphine-induced liver injury, does not influence the sedative effect of morphine, and is a powerful adjuvant for improving morphine hepatotoxicity. The honeysuckle extract is easy to obtain from plants, has good safety and can be widely produced and applied.
Description
Technical Field
The invention relates to the technical field of biomedicine, in particular to application of a honeysuckle extract, and particularly relates to application of the honeysuckle extract in preparation of a medicament for reducing morphine-induced hepatotoxicity.
Background
Abuse of opioids has become a serious social problem of concern at home and abroad. Morphine, a potent analgesic, is commonly used in the treatment of acute and chronic pain and is one of the opioids. However, the clinical use of morphine, which causes cell death and apoptosis in various systems and organs, has been very limited (NestlerEJ, AghajanianGK. molecular and cellular basis analysis. science.1997; 278: 58-63.Yin D, MufsonRA, WangR, ShiY. Fas-mediatedcell and protein book. Nature.1999; 397-218.HuS, ShengWS, Lokensgard JR, Peterson PK. Morphiloneindus dispensing of human tissue and neurones. neuropharmacology.2002; 42: 829-836.). Among them, morphine damage to the liver is significant and severe, which is a fact confirmed by the medical community. The search for drugs that protect liver damage caused by morphine is of great significance in reducing the side effects of morphine and in applying morphine more widely.
Morphine is a classical opioid drug, is a clinical common anesthetic, has a strong analgesic effect, and is used for severe pain caused by trauma, surgery, burns and the like. However, prolonged use of morphine can be toxic to the liver and kidneys. A large number of animal experiments show that the liver injury and oxidative stress reaction of mice can be caused by long-term injection of small dose morphine, so that the liver cells are subjected to apoptosis. Morphine, as a pair of double-edged sword, is both an effective analgesic and may also cause serious side effects. In order to achieve the clinical curative effect of morphine and solve the adverse reaction, the key point is to find the drug for reducing the liver toxicity of morphine.
The flos Lonicerae extract is the active ingredient of flos Lonicerae, and has various pharmacological effects including antiinflammatory and antibacterial, antioxidant, immunoregulatory, hepatoprotective and antitumor effects. The honeysuckle extract can obviously inhibit liver fibrosis and liver cell apoptosis, and reports show that the honeysuckle extract can reduce the hepatotoxicity caused by morphine, so the honeysuckle extract has important research significance in the clinical and scientific fields.
Disclosure of Invention
The invention provides application of an extract in preparing a medicament for reducing morphine-induced hepatotoxicity, and solves the problems in the prior art.
In order to solve the technical problems, the invention is realized by the following technical scheme:
an application of an extract in preparing a medicament for reducing morphine-induced hepatotoxicity, wherein the extract is a honeysuckle extract.
The flos Lonicerae extract has therapeutic application of inhibiting liver toxicity.
The dosage of flos Lonicerae extract is 0-10 g/kg.
Use of an extract in the preparation of a medicament for reducing morphine-induced hepatotoxicity, comprising the following analytical steps:
the method comprises the following steps: selecting male mice of 4 weeks old;
step two: dissolving flos Lonicerae extract in physiological saline, and preparing neutral formalin fixing solution, neutral resin, hematoxylin and eosin staining solution;
step three: dividing male mice into four groups, and performing four experiments including control group, morphine group, flos Lonicerae extract group and flos Lonicerae extract + morphine group, each group containing 8 mice;
step four: according to four groups of experiments, the influence of the honeysuckle extract on the morphine sedation effect, the influence of the honeysuckle extract on the AST and ALP levels in the serum of mice and the protective effect of the honeysuckle extract on the morphine-induced liver tissue injury of the mice are obtained.
The control group is prepared by injecting 1ml of normal saline into the abdominal cavity of the mouse every day on days 1-20; the morphine group is prepared by injecting 20mg/kg morphine into the abdominal cavity of the mouse every day on the 1 st to 5 th days, injecting 20mg/kg morphine every two days on the 6 th to 10 th days, and injecting 30mg/kg morphine every two days on the 11 th to 20 th days; the honeysuckle extract group is prepared by feeding 45g/kg of honeysuckle extract to the mice by intragastric administration every day on the 1 st to 20 th days; the honeysuckle extract + morphine group was continued for 20 days, and the mice received the same treatment as the morphine group and the honeysuckle extract group.
A medicament prepared from an extract in the application of preparing a medicament for reducing morphine-induced hepatotoxicity comprises a pharmaceutically effective amount of honeysuckle extract and a pharmaceutically acceptable carrier.
The pharmaceutical dosage forms comprise suspensions, emulsions, tablets, capsules, granules, oral liquids and injections.
The invention discloses a new clinical application of the traditional Chinese herbal medicine honeysuckle extract. The honeysuckle extract can obviously inhibit morphine-induced liver injury, does not influence the sedative effect of morphine, and is a powerful adjuvant for improving morphine hepatotoxicity. The honeysuckle extract is easy to obtain from plants, has good safety and can be widely produced and applied.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, and it is obvious that the drawings in the following description are only some embodiments of the present invention, and for those skilled in the art, other drawings can be obtained according to these drawings without creative efforts.
Figure 1 is a graph of the effect of honeysuckle extract on morphine sedation;
FIG. 2 is a graph of the effect of honeysuckle extract on levels of AST and ALP in serum of morphine-induced mice;
figure 3 is a graph of the effect of honeysuckle extract on morphine-induced liver tissue damage in mice.
Detailed Description
The following further describes the embodiments of the present invention. It should be noted that the description of the embodiments is provided to help understanding of the present invention, but the present invention is not limited thereto. In addition, the technical features involved in the embodiments of the present invention described below may be combined with each other as long as they do not conflict with each other.
An application of an extract in preparing a medicament for reducing morphine-induced hepatotoxicity, wherein the extract is a honeysuckle extract.
The flos Lonicerae extract has therapeutic application of inhibiting liver toxicity.
The dosage of flos Lonicerae extract is 0-10 g/kg.
Use of an extract in the preparation of a medicament for reducing morphine-induced hepatotoxicity, comprising the following analytical steps:
the method comprises the following steps: selecting male mice of 4 weeks old;
step two: dissolving flos Lonicerae extract in physiological saline, and preparing neutral formalin fixing solution, neutral resin, hematoxylin and eosin staining solution;
step three: dividing male mice into four groups, and performing four experiments including control group, morphine group, flos Lonicerae extract group and flos Lonicerae extract + morphine group, each group containing 8 mice;
step four: according to four groups of experiments, the influence of the honeysuckle extract on the morphine sedation effect, the influence of the honeysuckle extract on the AST and ALP levels in the serum of mice and the protective effect of the honeysuckle extract on the morphine-induced liver tissue injury of the mice are obtained.
The control group is prepared by injecting 1ml of normal saline into the abdominal cavity of the mouse every day on days 1-20; the morphine group is prepared by injecting 20mg/kg morphine into the abdominal cavity of the mouse every day on the 1 st to 5 th days, injecting 20mg/kg morphine every two days on the 6 th to 10 th days, and injecting 30mg/kg morphine every two days on the 11 th to 20 th days; the honeysuckle extract group is prepared by feeding 45g/kg of honeysuckle extract to the mice by intragastric administration every day on the 1 st to 20 th days; the honeysuckle extract + morphine group was continued for 20 days, and the mice received the same treatment as the morphine group and the honeysuckle extract group.
A medicament prepared from an extract in the application of preparing a medicament for reducing morphine-induced hepatotoxicity comprises a pharmaceutically effective amount of honeysuckle extract and a pharmaceutically acceptable carrier.
The pharmaceutical dosage forms comprise suspensions, emulsions, tablets, capsules, granules, oral liquids and injections.
The invention discloses a new clinical application of the traditional Chinese herbal medicine honeysuckle extract. The honeysuckle extract can obviously inhibit morphine-induced liver injury, does not influence the sedative effect of morphine, and is a powerful adjuvant for improving morphine hepatotoxicity. The honeysuckle extract is easy to obtain from plants, has good safety, and can be widely produced and applied in example 1: effect of honeysuckle extract on the sedative Effect of morphine
The sedative effects of morphine were evaluated by recording the time of the mice during the induction, anesthesia and recovery phases. The anaesthesia phase is as follows: induction phase (although mice fall, there are still various responses, breathing is mainly chest breathing); an anesthesia period: (mice are stable in breathing, even muscle is relaxed, limbs are not active, corneal reflex is weak, skin pain reaction, toe reaction disappears); the convalescent phase (various reflexes and reactions begin to recover, limbs begin to wobble). The results are shown in FIG. 1.
Example 2: effect of honeysuckle extract on AST and ALP levels in mouse serum
After sacrifice, midline laparotomy was performed. The liver was removed and blood was drawn by cardiac puncture. After centrifugation of the blood by density gradient centrifugation, the serum was separated for liver function testing. The AST and ALP contents in serum were measured by an automated biochemical analyzer. The results are shown in FIG. 2.
Example 3: protection effect of honeysuckle extract on morphine-induced mouse liver tissue injury
In the experiment, the protective effect of the honeysuckle extract on the morphine-induced liver tissue injury of the mouse is detected by H & E staining. Liver samples were fixed in 10% neutral formalin fixative. The fixed tissue was then dehydrated, cleared and embedded in paraffin. Paraffin embedded tissues were cut to 4 μm, then dried and deparaffinized. Tissue sections were stained with hematoxylin and eosin in sequence. The tissue sections were then sequentially dehydrated, deparaffinized and blocked with neutral resin. The results are shown in FIG. 3.
And (3) detection results:
1. the flos Lonicerae extract has no influence on the sedative effect of morphine
As shown in fig. 1, the time of the induction period, the sedation period and the recovery period of the honeysuckle extract + morphine group did not significantly affect the morphine group, indicating that the honeysuckle extract did not affect the sedation effect of morphine.
2. Flos Lonicerae extract can significantly reduce morphine-induced AST and ALP level increase
As shown in fig. 2, the levels of AST and ALP of the morphine group were significantly higher than those of the control group, while the levels of AST and ALP of the honeysuckle extract + morphine group were lower than those of the morphine group, indicating that the honeysuckle extract was effective in inhibiting the increase of ASR and ALP levels caused by morphine.
3. Flos Lonicerae extract can relieve morphine-induced liver injury
As shown in FIG. 3, the liver tissue of the control group was normal, while the liver tissue of the morphine group was significantly damaged, Copffer cytosis increased, and the central hepatic vein is enlarged. Morphine-induced liver tissue damage is alleviated after treatment with honeysuckle extract.
The embodiments of the present invention have been described in detail, but the present invention is not limited to the described embodiments. It will be apparent to those skilled in the art that various changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, and the scope of protection is still within the scope of the invention.
Claims (7)
1. Use of an extract for the preparation of a medicament for reducing morphine-induced hepatotoxicity, characterized in that: the extract is honeysuckle extract.
2. Use of an extract according to claim 1 for the preparation of a medicament for reducing morphine-induced hepatotoxicity, characterized in that: the flos Lonicerae extract has therapeutic application of inhibiting liver toxicity.
3. Use of an extract according to claim 1 or 2 for the preparation of a medicament for reducing morphine-induced hepatotoxicity, characterized in that: the dosage of flos Lonicerae extract is 0-10 g/kg.
4. Use of an extract according to claim 1 for the preparation of a medicament for reducing morphine-induced hepatotoxicity, characterized in that: the method comprises the following analysis steps:
the method comprises the following steps: selecting male mice of 4 weeks old;
step two: dissolving flos Lonicerae extract in physiological saline, and preparing neutral formalin fixing solution, neutral resin, hematoxylin and eosin staining solution;
step three: dividing male mice into four groups, and performing four experiments including control group, morphine group, flos Lonicerae extract group and flos Lonicerae extract + morphine group, each group containing 8 mice;
step four: according to four groups of experiments, the influence of the honeysuckle extract on the morphine sedation effect, the influence of the honeysuckle extract on the AST and ALP levels in the serum of mice and the protective effect of the honeysuckle extract on the morphine-induced liver tissue injury of the mice are obtained.
5. Use of an extract according to claim 4 for the preparation of a medicament for reducing morphine-induced hepatotoxicity, characterized in that: the control group is prepared by injecting 1ml of normal saline into the abdominal cavity of the mouse every day on days 1-20; the morphine group is prepared by injecting 20mg/kg morphine into the abdominal cavity of the mouse every day on the 1 st to 5 th days, injecting 20mg/kg morphine every two days on the 6 th to 10 th days, and injecting 30mg/kg morphine every two days on the 11 th to 20 th days; the honeysuckle extract group is prepared by feeding 45g/kg of honeysuckle extract to the mice by intragastric administration every day on the 1 st to 20 th days; the honeysuckle extract + morphine group was continued for 20 days, and the mice received the same treatment as the morphine group and the honeysuckle extract group.
6. A medicament prepared from the extract of claim 1 for use in the preparation of a medicament for reducing morphine-induced hepatotoxicity, wherein: the medicine contains a pharmaceutically effective amount of honeysuckle extract and a pharmaceutically acceptable carrier.
7. The use of an extract according to claim 6 in the preparation of a medicament for reducing morphine-induced hepatotoxicity, wherein: the pharmaceutical dosage forms comprise suspensions, emulsions, tablets, capsules, granules, oral liquids and injections.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110991802.3A CN113679751A (en) | 2021-08-27 | 2021-08-27 | Application of extract in preparation of medicines for reducing morphine-induced hepatotoxicity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110991802.3A CN113679751A (en) | 2021-08-27 | 2021-08-27 | Application of extract in preparation of medicines for reducing morphine-induced hepatotoxicity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113679751A true CN113679751A (en) | 2021-11-23 |
Family
ID=78583160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110991802.3A Pending CN113679751A (en) | 2021-08-27 | 2021-08-27 | Application of extract in preparation of medicines for reducing morphine-induced hepatotoxicity |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113679751A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106261362A (en) * | 2016-08-08 | 2017-01-04 | 南昌大学 | A kind of honeysuckle composition beverage with the liver protecting effect and preparation method |
-
2021
- 2021-08-27 CN CN202110991802.3A patent/CN113679751A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106261362A (en) * | 2016-08-08 | 2017-01-04 | 南昌大学 | A kind of honeysuckle composition beverage with the liver protecting effect and preparation method |
Non-Patent Citations (2)
| Title |
|---|
| 《中华人民共和国药典临床用药须知 2015年版 中药饮片卷》: "《中华人民共和国药典临床用药须知 2015年版 中药饮片卷》", 30 September 2017 * |
| 景恒翠等: "金银花的药用成分及药理分析", 《河南中医》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103145679B (en) | Preparation method and application of epigallocatechin gallate | |
| CN104873491A (en) | Application of schisandrin b and schizandrin c in preparation of anti-hepatic fibrosis drug | |
| EP1486213B1 (en) | The use of the total coumarins of cnidium monnieri in preparation of the medicament for treating psoriasis | |
| CN113679751A (en) | Application of extract in preparation of medicines for reducing morphine-induced hepatotoxicity | |
| CN108159114B (en) | Lamiophlomis rotata total iridoid glycoside extract, extraction method and application thereof | |
| CN112569222A (en) | Application of trifluroicaritin in preparation of medicine for improving pain, swelling and motor function | |
| CN103316103B (en) | Coccidian-expelling and dysentery-stopping mixture for livestock and preparation method thereof | |
| CN112521389A (en) | Medicament and method for promoting wound healing | |
| Elijah et al. | Paracetamol-induced liver damage and effect of prosopis africana seeds extract on liver marker enzymes of wistar albino rats | |
| WO2024002058A1 (en) | Plectranthus amboinicus extract for use in alleviation of radiation-induced skin disorders | |
| CN103830221A (en) | Applications of hydroxysafflor yellow A in preparation of medicines used for treating cardiovascular diseases | |
| CN101966245B (en) | Compound injection for curing viral diseases in livestock and poultry and preparation method thereof | |
| CN107375409B (en) | Application of bauhinia championii polymethoxyl total flavonoids in treatment and prevention of gastric ulcer | |
| CN106581027B (en) | Compound and pharmaceutical application, composition and preparation thereof | |
| CN1253780A (en) | Method for extracting active component of sea cockroach | |
| CN102008534A (en) | Antitubercular pharmaceutical composition containing balloonflower root extract | |
| CN103800318A (en) | Application of brazilin in preparing medicaments for preventing and treating liver and kidney injury | |
| Parker et al. | Paracetamol-Induced Liver Damage and Effect of Prosopis africana Seeds Extract on Liver Marker Enzymes of Wistar Albino Rats: Effect of Prosopis africana Seed Extract on Liver | |
| CN103446119B (en) | Application of Fluevirosines A in preparation of acute renal failure treating drug | |
| CN115177620A (en) | Application of seolonide or pharmaceutically acceptable salt thereof in preparation of medicine for preventing or treating follicular lymphoma | |
| CN113456643A (en) | Pharmaceutical composition containing plinabulin and application thereof | |
| CN114288285A (en) | Application of epigallocatechin gallate in preparing medicine for preventing or treating systemic poisoning of medusa toxin | |
| Cowan et al. | Tachyphylaxis III. Ephedrine | |
| CN113456636A (en) | Application of flufenidone in preparation of acute liver injury medicine | |
| CN110123871A (en) | A kind of Chinese medicinal composition preparation and preparation method promoting leucocyte and toxin expelling effect |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211123 |